Key Highlights
● uniQure furnished a September 29, 2026 8-K with 36-month and 48-month follow-up for AMT-130, its Huntington's disease gene therapy.
● At 36 months, the company reports an 80 percent cUHDRS slowing in high-dose patients versus an external control.
● At 48 months, the release reports 44 percent cUHDRS slowing that did not reach statistical significance (p-value 0.144).
● The company says the FDA said 36-month data from 12 high-dose patients would be an acceptable primary BLA basis.
uniQure N.V. (NASDAQ:QURE) filed a Form 8-K on September 29, 2026, furnishing a corporate presentation and a press release that update clinical results for AMT-130, its investigational gene therapy for Huntington's disease. The press release reports 36-month and 48-month follow-up, which the company describes as showing continued slowing of disease progression, and restates where the company's regulatory submission stands. The filing reports under Item 7.01 (Regulation FD Disclosure) and Item 9.01, with the presentation and press release attached as exhibits.
What the New Data Show
The press release describes 36-month results from 15 high-dose patients and 48-month results from 12 high-dose and 12 low-dose patients. Outcomes are compared with an external control built from 1,337 propensity score-matched participants from an updated ENROLL-HD dataset, rather than with a concurrent untreated group.
At 36 months, the company reports that high-dose patients showed an 80 percent slowing of disease progression on the composite Unified Huntington's Disease Rating Scale (cUHDRS), with a nominal p-value of 0.005, and a 67 percent slowing on Total Functional Capacity (TFC), with a nominal p-value of 0.011, both compared with the updated external control. At 48 months, the reported slowing was 44 percent on cUHDRS, which the release says did not reach statistical significance (p-value 0.144), and 61 percent on TFC, with a nominal p-value of 0.008.
The press release also reports mean cerebrospinal fluid neurofilament light chain (NfL), a biomarker of nerve-cell damage, at 6 percent below baseline at 36 months and 4 percent above baseline at 48 months. Because the comparison is with an external control rather than a concurrent untreated group, these are indirect comparisons, and the release labels several of the p-values as nominal.
Regulatory Position
The key regulatory statement comes from the press release: at a June 2026 Type B meeting, "the FDA communicated that the 36-month data from 12 high-dose patients would be acceptable as the primary basis for the BLA submission under the Accelerated Approval pathway, and the submission was made accordingly." This is the company's account of the FDA discussion. The press release lists Breakthrough Therapy, Regenerative Medicine Advanced Therapy (RMAT) and Fast Track designations for the program. The materials reviewed do not say when the FDA will act on the application, and they do not state that the agency has approved anything.
The 48-month figures are longer-term follow-up rather than the basis of the submission, which the release ties to 36-month data from 12 high-dose patients. The new 36-month figures in this update cover 15 high-dose patients, so the two 36-month datasets are not identical.
Safety and Limitations
The presentation says AMT-130 "continues to be generally well-tolerated," and that the most common adverse events related to the administration procedure and resolved. The press release also reports that, since the September 2025 data readout, one patient in the low-dose group died by suicide about five years after treatment; the presentation says this was assessed as unrelated to treatment.
The results rest on an external-control comparison, which carries inherent uncertainty. The release itself says the 48-month cUHDRS result did not reach statistical significance, and other p-values are described as nominal.
The company scheduled a conference call for 8:30 a.m. Eastern time on Tuesday, September 29, 2026.
AMT-130 BLA Status and Open FDA Questions
The company's materials give no date for an FDA decision on the BLA.






Please wait processing your request...